McClarren Financial Advisors Inc. Has $151,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

McClarren Financial Advisors Inc. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2,381.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,838 shares of the biopharmaceutical company’s stock after buying an additional 4,643 shares during the period. McClarren Financial Advisors Inc.’s holdings in Pfizer were worth $151,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of PFE. Olistico Wealth LLC acquired a new position in Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter worth $29,000. Quarry LP bought a new stake in shares of Pfizer in the 2nd quarter worth $31,000. Trivant Custom Portfolio Group LLC grew its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the 2nd quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.05 on Friday, reaching $29.22. The stock had a trading volume of 24,244,872 shares, compared to its average volume of 37,106,250. The business’s 50 day moving average is $29.07 and its two-hundred day moving average is $28.44. The company has a market cap of $165.58 billion, a P/E ratio of -487.00, a price-to-earnings-growth ratio of 1.02 and a beta of 0.67. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $25.20 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue was up 2.1% compared to the same quarter last year. During the same period last year, the firm posted $0.67 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.75%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on PFE. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Sanford C. Bernstein started coverage on shares of Pfizer in a research report on Thursday. They set a “market perform” rating and a $32.00 price target for the company. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company increased their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $33.91.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.